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within the NSAID class and other therapeutic classes that
constitute the analgesic market. METHODS: The study
design was a retrospective study of paid pharmacy claims
for analgesic medications for a continuously insured pop-
ulation of 62,614 members from July 1996 to June 2001.
Claims were divided into seven therapeutic categories:
hydrocodone, narcotics, non-narcotics, newer NSAIDs
(Relafen, Daypro, Arthrotec), older NSAIDs, oxycodone,
and COX-2 inhibitors. Data of paid analgesic pharmacy
claims were analyzed by overall analgesic market pre-
scription claims, day supply, pain management therapies,
per diem cost (ingredient cost per day supply) and market
share per therapeutic category. RESULTS: Over the 5-
year period, claims increased 29.1% while day supply per
claim increased 17.7% for a total growth in day supply
of almost 52%. The proportion of the population who
used an analgesic also increased from 33.4% in the ﬁrst
year to 37.9% in the ﬁfth year. There was a 15% increase
in people receiving at least one analgesic prescription in
a year over the 5-year period. Per diem costs for the
market increased from $1.74 in the ﬁrst year to $2.20 
in the ﬁfth year. Per member per month costs increased
69.3% from $12.36 in the ﬁrst year to $20.93 in the ﬁfth
year. COX-2 inhibitors market share by day supply
increased from zero to 39.6%. The market share of the
newer NSAIDs decreased from 20.5% in the year prior
to the introduction of the COX-2 inhibitors (year 2) 
to 5.5% in the ﬁfth year. CONCLUSIONS: Based on 
day supply, the analgesic market grew almost 52% with
COX-2 inhibitors garnering 39.6% within 3 years of
market introduction. The COX-2’s beneﬁted from both
the growth in the market and reduction in market share
of the newer NSAIDs.
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OBJECTIVES: Although it is well recognized, in both
clinical research and actual practice, that non-compliance
with osteoporosis treatment is a problem, its economic
implications have not been well documented. The objec-
tive of this study was to quantify the implications of non-
compliance in terms of all-cause hospitalizations and total
costs. METHODS: Demographic, prescription drug use,
physician services and hospitalization information for
women with osteoporosis who were dispensed an osteo-
porosis medication between 1996 and 2001 was obtained
from the Saskatchewan Health data ﬁles. Subjects were
considered to be compliant over a given period of time if
they had medication available during 80% or more of
that time interval. Hospitalization rates and total costs in
various patient groups were compared using descriptive
analyses. The impact of compliance was assessed further
using regression analysis on the logarithmically trans-
formed total cost, controlling for prior history of hospi-
talizations (which was considered a proxy for morbidity).
RESULTS: A total of 11,249 women suffering from
osteoporosis were identiﬁed with an average follow-up of
2.3 years. More than half (50.6%) did not have medica-
tion available to cover at least 80% of the time they 
were followed and were thus considered non-compliant.
Overall, 48.5% of patients were hospitalized an average
of 2.7 times during follow-up. Non-compliant patients
were signiﬁcantly more likely to be hospitalized (54.3%)
than compliant patients (42.6%) (P < 0.0001). The total
monthly cost—including both hospitalization and physi-
cian service costs—was signiﬁcantly higher for non-
compliant ($245 CAD) than for compliant ($214 CAD)
patients (P < 0.05). The same trend was observed for both
cost components individually. The effect of compliance
on total cost was maintained after controlling for hospi-
talization history. CONCLUSION: The desired goal of
keeping patients with osteoporosis on chronic treatment
is not achieved adequately in actual practice and the cost
implications of this behavior are substantial.
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